Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Second Sight on go to start study of Orion Cortical Visual Prosthesis

Published 11/02/2017, 09:17 AM
© Reuters.  Second Sight on go to start study of Orion Cortical Visual Prosthesis
VANI
-
  • The FDA has signed off on a clinical feasibility study evaluating Second Sight Medical's (NASDAQ:EYES) Orion Cortical Visual Prosthesis System. The approval allows two U.S. sites, UCLA and Baylor, to enroll up a total of five patients.
  • Orion is designed to stimulate the brain's visual cortex in order to produce the perception of patterns of light in completely blind people. Like the Argus II, images captured by a small camera mounted on the person's glasses are wirelessly transmitted to an array of electrodes (in this case on the visual cortex instead of the retina) which produces the perception of patterns of light.
  • Shares are up 19% premarket, stoked by the announcement of 2018 Medicare reimbursement for the Argus II.
  • Previously: Medicare to pay $122.5K for implanting Second Sight's Argus II in 2018; shares ahead 14% premarket (Nov. 2)
  • Now read: Medicare to pay 2.5K for implanting Second Sight's Argus II in 2018; shares ahead 14% premarket


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.